adMare
News
May 01 2025
Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing
April 10 2025
Two key experts joining Find Therapeutics to accelerate the development of FTX-101
February 19 2025
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens
February 07 2025
Government of Canada invests $6 million to drive growth in B.C.’s life sciences sector
December 04 2024
adMare BioInnovations Welcomes Cohort VII of the Executive Institute, Strengthening Canada’s Life Sciences Leadership
December 02 2024
KisoJi Biotechnology Raises $41 Million to Advance Lead Program Into the Clinic and Deploy AI Tools Into Key Pipeline Indications
November 28 2024
adMare BioInnovations Spins Out Analytical Services to Paraza Pharma, Catalyzing Growth and Innovation
November 21 2024
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
November 15 2024
Thryv Therapeutics Announces Completion of Phase 1 Dosing of its Second Novel SGK1 Inhibitor THRV-1268 - Future Studies in Heart Failure and Atrial Fibrillation to Commence in 2025ucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing
Newsletter
Stay up to date on the
latest adMare news
Vancouver Innovation Centre
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
T. 604.827.1147
Toronto Office
MaRS Centre, West Tower
661 University Ave., Suite 415
Toronto, Ontario, Canada
M5G 1M1
T. 416.673.8100
Montreal Innovation Centre
7171 Frederick-Banting
Montréal, Québec, Canada
H4S 1Z9
